메뉴 건너뛰기




Volumn 27, Issue 4, 2013, Pages

Recurrent epithelial ovarian cancer: An update on treatment

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FARLETUZUMAB; GEMCITABINE; INIPARIB; OLAPARIB; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN;

EID: 84876207877     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (115)

References (69)
  • 2
    • 0025253463 scopus 로고
    • Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials
    • Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322:1021-7.
    • (1990) N Engl J Med , vol.322 , pp. 1021-1027
    • Young, R.C.1    Walton, L.A.2    Ellenberg, S.S.3
  • 3
    • 0027395983 scopus 로고
    • Second-line chemotherapy for recurrent carcinoma of the ovary
    • Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 1993;71(4 suppl):1559-64.
    • (1993) Cancer , vol.71 , Issue.4 SUPPL. , pp. 1559-1564
    • Thigpen, J.T.1    Vance, R.B.2    Khansur, T.3
  • 4
    • 4143087249 scopus 로고    scopus 로고
    • Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
    • Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120-5.
    • (2004) J Clin Oncol , vol.22 , pp. 3120-3125
    • Markman, M.1    Markman, J.2    Webster, K.3
  • 5
    • 1542364058 scopus 로고    scopus 로고
    • Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): A GINECO study
    • Abstr
    • Pujade-Lauraine E, Paraiso D, Cure H, et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. J Clin Oncol. 2002;21:Abstr 829.
    • (2002) J Clin Oncol , vol.21 , pp. 829
    • Pujade-Lauraine, E.1    Paraiso, D.2    Cure, H.3
  • 6
    • 33644516543 scopus 로고    scopus 로고
    • Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range
    • Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-43.
    • (2005) J Clin Oncol , vol.23 , pp. 9338-9343
    • Santillan, A.1    Garg, R.2    Zahurak, M.L.3
  • 7
    • 34548513054 scopus 로고    scopus 로고
    • An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy
    • Liu PY, Alberts DS, Monk BJ, et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25:3615-20.
    • (2007) J Clin Oncol , vol.25 , pp. 3615-3620
    • Liu, P.Y.1    Alberts, D.S.2    Monk, B.J.3
  • 8
    • 0034692452 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup
    • Vergote I, Rustin GJ, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534-5.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 1534-1535
    • Vergote, I.1    Rustin, G.J.2    Eisenhauer, E.A.3
  • 9
    • 0035281501 scopus 로고    scopus 로고
    • Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer
    • Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19:1266-74.
    • (2001) J Clin Oncol , vol.19 , pp. 1266-1274
    • Doyle, C.1    Crump, M.2    Pintilie, M.3    Oza, A.M.4
  • 10
    • 0036498921 scopus 로고    scopus 로고
    • Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubucin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
    • Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubucin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002; 20:1232-7.
    • (2002) J Clin Oncol , vol.20 , pp. 1232-1237
    • Cantu, M.G.1    Buda, A.2    Parma, G.3
  • 11
    • 0026086870 scopus 로고
    • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
    • Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9:389-93.
    • (1991) J Clin Oncol , vol.9 , pp. 389-393
    • Markman, M.1    Rothman, R.2    Hakes, T.3
  • 12
    • 34548150183 scopus 로고    scopus 로고
    • Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: A phase II study
    • Ferrandina G, Ludovisi M, De Vicenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol. 2007;18:1348-53.
    • (2007) Ann Oncol , vol.18 , pp. 1348-1353
    • Ferrandina, G.1    Ludovisi, M.2    de Vicenzo, R.3
  • 13
    • 19744368302 scopus 로고    scopus 로고
    • Cancer of the ovary
    • Canistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
    • (2004) N Engl J Med , vol.351 , pp. 2519-2529
    • Canistra, S.A.1
  • 14
    • 68749099837 scopus 로고    scopus 로고
    • A randomized trial in ovarian cancer (OC) or early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)
    • Abstr
    • Rustin GJ, van der Burg ME, et al. A randomized trial in ovarian cancer (OC) or early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol. 2009; 27(18 suppl):Abstr 1.
    • (2009) J Clin Oncol , vol.27 , Issue.18 SUPPL. , pp. 1
    • Rustin, G.J.1    van der Burg, M.E.2
  • 15
    • 0036498921 scopus 로고    scopus 로고
    • Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
    • Cantù MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002;20:1232-7.
    • (2002) J Clin Oncol , vol.20 , pp. 1232-1237
    • Cantù, M.G.1    Buda, A.2    Parma, G.3
  • 16
    • 0036499081 scopus 로고    scopus 로고
    • Is there a best choice of second-line agent in thetreatment of recurrent, potentially platinum-sensitive ovarian cancer?
    • Cannistra SA. Is there a best choice of second-line agent in thetreatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 2002; 20:1158-60.
    • (2002) J Clin Oncol , vol.20 , pp. 1158-1160
    • Cannistra, S.A.1
  • 17
    • 0037862963 scopus 로고    scopus 로고
    • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2-2 trial
    • Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2-2 trial. Lancet. 2003;361:2099-2106.
    • (2003) Lancet , vol.361 , pp. 2099-2106
    • Parmar, M.K.1    Ledermann, J.A.2    Colombo, N.3
  • 18
    • 33750588670 scopus 로고    scopus 로고
    • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
    • Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707.
    • (2006) J Clin Oncol , vol.24 , pp. 4699-4707
    • Pfisterer, J.1    Plante, M.2    Vergote, I.3
  • 19
    • 68749121487 scopus 로고    scopus 로고
    • A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC). CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)
    • Abstr
    • Pujade-Lauraine E, Mahner S, Kaem J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC). CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol. 2009;27:(18 suppl): Abstr LBA5509.
    • (2009) J Clin Oncol , vol.27 , Issue.18 SUPPL.
    • Pujade-Lauraine, E.1    Mahner, S.2    Kaem, J.3
  • 20
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A GOG study
    • Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a GOG study. J Clin Oncol. 2007;25:5165-71.
    • (2007) J Clin Oncol , vol.25 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3
  • 21
    • 37849035249 scopus 로고    scopus 로고
    • Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia
    • Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J Clin Oncol. 2008;26:76-82.
    • (2008) J Clin Oncol , vol.26 , pp. 76-82
    • Garcia, A.A.1    Hirte, H.2    Fleming, G.3
  • 22
    • 36849056497 scopus 로고    scopus 로고
    • Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    • Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6.
    • (2007) J Clin Oncol , vol.25 , pp. 5180-5186
    • Cannistra, S.A.1    Matulonis, U.A.2    Penson, R.T.3
  • 24
    • 84861736119 scopus 로고    scopus 로고
    • OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol. 2012;30:2039.
    • J Clin Oncol , vol.2012 , pp. 30
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3
  • 25
    • 78649361197 scopus 로고    scopus 로고
    • A randomized phase III study of trabectedin with pegulated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer
    • Stockholm, Sweden, Abstr
    • Monk BJ, Herzog T, Kaye S, et al. A randomized phase III study of trabectedin with pegulated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer. Proceedings of the 33rd ESMO Congress, Stockholm, Sweden, 2008:Abstr LBA4.
    • (2008) Proceedings of the 33rd ESMO Congress
    • Monk, B.J.1    Herzog, T.2    Kaye, S.3
  • 26
    • 34648829056 scopus 로고    scopus 로고
    • Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
    • Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107:118-23.
    • (2007) Gynecol Oncol , vol.107 , pp. 118-123
    • Simpkins, F.1    Belinson, J.L.2    Rose, P.G.3
  • 27
    • 0024327106 scopus 로고
    • Taxol: A unique antineoplastic agent with significant activity in advanced ovarian adenocarcinoma
    • McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian adenocarcinoma. Ann Intern Med. 1989;111:273-9.
    • (1989) Ann Intern Med , vol.111 , pp. 273-279
    • McGuire, W.P.1    Rowinsky, E.K.2    Rosenshein, N.B.3
  • 28
    • 0027055485 scopus 로고
    • Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma
    • Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 1992;10:1748-53.
    • (1992) J Clin Oncol , vol.10 , pp. 1748-1753
    • Einzig, A.I.1    Wiernik, P.H.2    Sasloff, J.3
  • 29
    • 0028153230 scopus 로고
    • Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A GOG study
    • Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a GOG study. J Clin Oncol. 1994;12:1748-53.
    • (1994) J Clin Oncol , vol.12 , pp. 1748-1753
    • Thigpen, J.T.1    Blessing, J.A.2    Ball, H.3
  • 30
    • 0028078681 scopus 로고
    • Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer
    • Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994;86:18-24.
    • (1994) J Natl Cancer Inst , vol.86 , pp. 18-24
    • Kohn, E.C.1    Sarosy, G.2    Bicher, A.3
  • 31
    • 0028020890 scopus 로고
    • Phase II study of gemcitabine (2,2-difluorodeoxycytidine) in previously treated ovarian cancer patients
    • Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2,2-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86:1530-3.
    • (1994) J Natl Cancer Inst , vol.86 , pp. 1530-1533
    • Lund, B.1    Hansen, O.P.2    Theilade, K.3
  • 32
    • 34447570846 scopus 로고    scopus 로고
    • Randomized phase III trial of gemcitabine compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
    • Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-8.
    • (2007) J Clin Oncol , vol.25 , pp. 2811-2818
    • Mutch, D.G.1    Orlando, M.2    Goss, T.3
  • 33
    • 33745994656 scopus 로고    scopus 로고
    • Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study
    • Petru E, Angleitner-Boubenizek L, Reinthaller A, et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 2006;102:226-9.
    • (2006) Gynecol Oncol , vol.102 , pp. 226-229
    • Petru, E.1    Angleitner-Boubenizek, L.2    Reinthaller, A.3
  • 34
    • 84865675658 scopus 로고    scopus 로고
    • Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone
    • Jul 2, Epub ahead of print
    • Krasner C, Poveda A, Herzog TJ, et al. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol. 2012; Jul 2. [Epub ahead of print]
    • (2012) Gynecol Oncol
    • Krasner, C.1    Poveda, A.2    Herzog, T.J.3
  • 35
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-22.
    • (2001) J Clin Oncol , vol.19 , pp. 3312-3322
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3
  • 36
    • 1542274149 scopus 로고    scopus 로고
    • Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in epithelial ovarian cancer
    • Abstr
    • Gordon AN, Teitelbaum A. Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in epithelial ovarian cancer. Eur J Cancer. 2003;12:Abstr S51.
    • (2003) Eur J Cancer , vol.12
    • Gordon, A.N.1    Teitelbaum, A.2
  • 37
    • 0005323412 scopus 로고    scopus 로고
    • A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer
    • Abstr
    • OByrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol. 2002;21:Abstr 808.
    • (2002) Proc Am Soc Clin Oncol , vol.21 , pp. 808
    • Obyrne, K.J.1    Bliss, P.2    Graham, J.D.3
  • 38
    • 0031055830 scopus 로고    scopus 로고
    • Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
    • Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987-93.
    • (1997) J Clin Oncol , vol.15 , pp. 987-993
    • Muggia, F.M.1    Hainsworth, J.D.2    Jeffers, S.3
  • 39
    • 0034903028 scopus 로고    scopus 로고
    • Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A retrospective comparative study of single-agent dosages
    • Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82:323-8.
    • (2001) Gynecol Oncol , vol.82 , pp. 323-328
    • Rose, P.G.1    Maxson, J.H.2    Fusco, N.3
  • 40
    • 9244247616 scopus 로고    scopus 로고
    • Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
    • Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552-7.
    • (1996) J Clin Oncol , vol.14 , pp. 1552-1557
    • Kudelka, A.P.1    Tresukosol, D.2    Edwards, C.L.3
  • 41
    • 0031781459 scopus 로고    scopus 로고
    • Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
    • Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16:2233-7.
    • (1998) J Clin Oncol , vol.16 , pp. 2233-2237
    • Hoskins, P.1    Eisenhauer, E.2    Beare, S.3
  • 42
    • 0035060411 scopus 로고    scopus 로고
    • Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma
    • Sorensen P, Hoyer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001; 81:58-62.
    • (2001) Gynecol Oncol , vol.81 , pp. 58-62
    • Sorensen, P.1    Hoyer, M.2    Jakobsen, A.3
  • 43
    • 0032936206 scopus 로고    scopus 로고
    • Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
    • Burger RA, DiSaia PJ, Roberts JA, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol. 1999;72:148-53.
    • (1999) Gynecol Oncol , vol.72 , pp. 148-153
    • Burger, R.A.1    Disaia, P.J.2    Roberts, J.A.3
  • 44
    • 0018595569 scopus 로고
    • Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: A Gynecologic Oncology Group study
    • Slayton RE, Creasman WT, Petty W, et al. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979;63:2089-94.
    • (1979) Cancer Treat Rep , vol.63 , pp. 2089-2094
    • Slayton, R.E.1    Creasman, W.T.2    Petty, W.3
  • 45
    • 0031894188 scopus 로고    scopus 로고
    • Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A GOG study
    • Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a GOG study. J Clin Oncol. 1998;16:405-10.
    • (1998) J Clin Oncol , vol.16 , pp. 405-410
    • Rose, P.G.1    Blessing, J.A.2    Mayer, A.R.3    Homesley, H.D.4
  • 46
    • 0037331627 scopus 로고    scopus 로고
    • A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study
    • Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-5.
    • (2003) Gynecol Oncol , vol.88 , pp. 130-135
    • Rose, P.G.1    Blessing, J.A.2    Ball, H.G.3
  • 47
    • 1642264781 scopus 로고    scopus 로고
    • Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum
    • Markman M, Zanotti K, Webster K, et al. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol. 2003;91:573-6.
    • (2003) Gynecol Oncol , vol.91 , pp. 573-576
    • Markman, M.1    Zanotti, K.2    Webster, K.3
  • 48
    • 0026599140 scopus 로고
    • Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
    • Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992;10:243-8.
    • (1992) J Clin Oncol , vol.10 , pp. 243-248
    • Markman, M.1    Hakes, T.2    Reichman, B.3
  • 49
    • 77955591543 scopus 로고    scopus 로고
    • A phase II evaluation of pemetrexed (LY231514, IND#40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecology Oncology Group
    • Abstr
    • Miller DS, Blessing JA, Krasner CN, Mannel RJ. A phase II evaluation of pemetrexed (LY231514, IND#40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecology Oncology Group. J Clin Oncol. 2008;26(suppl):Abstr 5524.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. , pp. 5524
    • Miller, D.S.1    Blessing, J.A.2    Krasner, C.N.3    Mannel, R.J.4
  • 50
    • 84859523588 scopus 로고    scopus 로고
    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
    • Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382.
    • (2012) N Engl J Med , vol.366 , pp. 1382
    • Ledermann, J.1    Harter, P.2    Gourley, C.3
  • 53
    • 80053578082 scopus 로고    scopus 로고
    • A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer
    • Abstr
    • Penson RT, Whalen C, Lasonde B, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2011;29:Abstr 5004.
    • (2011) J Clin Oncol , vol.29 , pp. 5004
    • Penson, R.T.1    Whalen, C.2    Lasonde, B.3
  • 54
    • 0027999966 scopus 로고
    • European-Candadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose verus low-dose and long versus short infusion
    • Eisenhauer EA, ten Bokkel Huinin WW, Swenerton KD, et al. European-Candadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose verus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654-66.
    • (1994) J Clin Oncol , vol.12 , pp. 2654-2666
    • Eisenhauer, E.A.1    ten Bokkel, H.W.W.2    Swenerton, K.D.3
  • 55
    • 0036570041 scopus 로고    scopus 로고
    • Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refactory ovarian cancer
    • Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refactory ovarian cancer. J Clin Oncol. 2002;20:2365-9.
    • (2002) J Clin Oncol , vol.20 , pp. 2365-2369
    • Markman, M.1    Hall, J.2    Spitz, D.3
  • 56
    • 10744230285 scopus 로고    scopus 로고
    • The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
    • Kita L, Kikuchi Y, Takano M, et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol. 2004;92:813-18.
    • (2004) Gynecol Oncol , vol.92 , pp. 813-818
    • Kita, L.1    Kikuchi, Y.2    Takano, M.3
  • 57
    • 33646562149 scopus 로고    scopus 로고
    • Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
    • Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-40.
    • (2006) Gynecol Oncol , vol.101 , pp. 436-440
    • Markman, M.1    Blessing, J.2    Rubin, S.C.3
  • 58
    • 0033813383 scopus 로고    scopus 로고
    • Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
    • Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000;78:369-72.
    • (2000) Gynecol Oncol , vol.78 , pp. 369-372
    • Markman, M.1    Kennedy, A.2    Webster, K.3
  • 60
    • 0033995249 scopus 로고    scopus 로고
    • Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
    • McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:1062-7.
    • (2000) J Clin Oncol , vol.18 , pp. 1062-1067
    • McGuire, W.P.1    Blessing, J.A.2    Bookman, M.A.3
  • 61
    • 0031786482 scopus 로고    scopus 로고
    • Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that combined cisplatin or carboplatin and paclitaxel
    • Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that combined cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345-62.
    • (1998) J Clin Oncol , vol.16 , pp. 3345-3362
    • Bookman, M.A.1    Malmstrom, H.2    Bolis, G.3
  • 62
    • 9244247616 scopus 로고    scopus 로고
    • Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
    • Kudelka AP, Trresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552-7.
    • (1996) J Clin Oncol , vol.14 , pp. 1552-1557
    • Kudelka, A.P.1    Trresukosol, D.2    Edwards, C.L.3
  • 63
    • 0031781459 scopus 로고    scopus 로고
    • Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
    • Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16:2233-7.
    • (1998) J Clin Oncol , vol.16 , pp. 2233-2237
    • Hoskins, P.1    Eisenhauer, E.2    Beare, S.3
  • 64
    • 0037331801 scopus 로고    scopus 로고
    • Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer
    • Brown JV, Peters WA, Rettenmaier MA, et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 2003;88:136-40.
    • (2003) Gynecol Oncol , vol.88 , pp. 136-140
    • Brown, J.V.1    Peters, W.A.2    Rettenmaier, M.A.3
  • 65
    • 33750191919 scopus 로고    scopus 로고
    • Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer
    • Herzog TJ, Powel MA, Rader JS, et al. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006;103:637-41.
    • (2006) Gynecol Oncol , vol.103 , pp. 637-641
    • Herzog, T.J.1    Powel, M.A.2    Rader, J.S.3
  • 66
    • 33947325163 scopus 로고    scopus 로고
    • Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer
    • Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105:205-10.
    • (2007) Gynecol Oncol , vol.105 , pp. 205-210
    • Safra, T.1    Menczer, J.2    Bernstein, R.3
  • 67
    • 37349023136 scopus 로고    scopus 로고
    • Weekly topotecan for recurrent platinum resistant ovarian cancer
    • Abushahin G, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008;108:53-7.
    • (2008) Gynecol Oncol , vol.108 , pp. 53-57
    • Abushahin, G.1    Singh, D.K.2    Lurain, J.R.3
  • 68
    • 0043125703 scopus 로고    scopus 로고
    • Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: Results of a multicenter phase III trial in patients with advanced gynecologic malignancies
    • Gold MA, Walker JL, Berek JS, et al. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol. 2003;90:325-30.
    • (2003) Gynecol Oncol , vol.90 , pp. 325-330
    • Gold, M.A.1    Walker, J.L.2    Berek, J.S.3
  • 69
    • 84866493383 scopus 로고    scopus 로고
    • AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
    • Abstr
    • Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012;30:Abstr LBA5002.
    • (2012) J Clin Oncol , vol.30
    • Pujade-Lauraine, E.1    Hilpert, F.2    Weber, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.